Bicara Therapeutics Inc (BCAX)

Feb 11, 2025, 4:01 PM EST - 11 days ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jan 27, 2025, 8:00 AM EST - 26 days ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Nov 12, 2024, 7:30 AM EST - 3 months ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 4:01 PM EST - 3 months ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:01 PM EDT - 5 months ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 14, 2024, 5:00 AM EDT - 5 months ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

GLXG MBX TDTH XCH ZBIO

Sep 13, 2024, 1:28 PM EDT - 5 months ago

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Sep 12, 2024, 9:15 PM EDT - 5 months ago

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Sep 11, 2024, 6:34 PM EDT - 5 months ago

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

Sep 7, 2024, 1:25 AM EDT - 6 months ago

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

BIOA PMAX PTHL ZBIO

Sep 6, 2024, 7:25 AM EDT - 6 months ago

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Aug 27, 2024, 2:19 PM EDT - 6 months ago

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

Aug 22, 2024, 5:29 PM EDT - 6 months ago

Oncology biotech Bicara Therapeutics files for a $200 million IPO

Aug 22, 2024, 4:38 PM EDT - 6 months ago

Bicara Therapeutics IPO Registration Document (S-1)